Toll like receptor‐9 agonists stimulate prostate cancer invasion in vitro
Identifieur interne : 001A90 ( Main/Exploration ); précédent : 001A89; suivant : 001A91Toll like receptor‐9 agonists stimulate prostate cancer invasion in vitro
Auteurs : Joanna M. Ilvesaro [États-Unis] ; Melinda A. Merrell [États-Unis] ; Telisha Millender Swain [États-Unis] ; Jennifer Davidson [États-Unis] ; Majd Zayzafoon [États-Unis] ; Kevin W. Harris [États-Unis] ; Katri S. Selander [États-Unis]Source :
- The Prostate [ 0270-4137 ] ; 2007-05-15.
English descriptors
- Teeft :
- Adenocarcinoma, Brain cancer cells, Breast cancer cells, Cancer cells, Cancer immunotherapy, Chloroquine, Clinical samples, Color figure, Culture medium, Endogenous ligands, Endoplasmic reticulum, Epithelial, Epithelial cancer cells, Epithelial cells, Estradiol, Human prostate cancer, Human prostate cancer cell lines, Human prostate cancer cells, Immunohistochemical detection, Immunol, Invasion intlr9, Life technologies, Ligand, Lncap, Lncap cells, Lower wells, Microbial, Microbial components, Negative staining control, Neutralizing antibody, Normal culture medium, Novel mechanism, Nucleic acids, Pca2b cells, Pca2b prostate cancer cells, Primary antibody, Prostate, Prostate cancer, Prostate cancer cells, Prostate cancer invasion, Prostate cancer progression, Prostate cancer risk, Prostate carcinogenesis, Prostate gland, Receptor, Receptors tlr4, Steroid biochem, Stromal cells, Subcellular localization, Synthetic inhibitors, Testosterone, Testosterone tlr9 expression, Tlr9, Tlr9 agonistic, Tlr9 agonists, Tlr9 expression, Tlr9 ligands, Tlr9 subfamily, Tlrs, Various tlrs.
Abstract
BACKGROUND: Toll‐like receptor 9 (TLR9) recognizes microbial DNA. In addition to immune cells, TLR9 expression has been detected in various cancer cells. We showed recently that TLR9 agonistic CpG‐oligonucleotides (CpG‐ODNs) induce matrix metalloproteinase‐13 (MMP‐13)‐mediated invasion in TLR9‐expressing (TLR9+) breast cancer cells. We investigated here TLR9 expression and function in human prostate cancer (CaP) cells. METHODS: TLR9 expression was detected with Western blotting and immunohistochemistry. Invasion was studied with Matrigel‐assays. MMP‐13 was assayed with ELISA. RESULTS: Human CaP cell lines and clinical samples exhibit various levels of TLR9 expression. Treatment of TLR9+, but not TLR9− CaP cells with CpG‐ODNs or bacterial DNA increased their invasion, which was inhibited with chloroquine. CpG‐ODN‐treatment also increased MMP‐13 activity and neutralizing anti‐MMP‐13 antibody prevented CpG‐ODN‐induced invasion in TLR9+ CaP cells. Estradiol up‐regulated TLR9 expression in LnCaP cells. CONCLUSIONS: TLR9‐mediated invasion may represent a novel mechanism through which infections promote prostate cancer. Prostate 67: 774–781, 2007. © 2007 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/pros.20562
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000792
- to stream Istex, to step Curation: 000792
- to stream Istex, to step Checkpoint: 000973
- to stream Main, to step Merge: 001B01
- to stream Main, to step Curation: 001A90
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toll like receptor‐9 agonists stimulate prostate cancer invasion in vitro</title><author><name sortKey="Ilvesaro, Joanna M" sort="Ilvesaro, Joanna M" uniqKey="Ilvesaro J" first="Joanna M." last="Ilvesaro">Joanna M. Ilvesaro</name></author><author><name sortKey="Merrell, Melinda A" sort="Merrell, Melinda A" uniqKey="Merrell M" first="Melinda A." last="Merrell">Melinda A. Merrell</name></author><author><name sortKey="Swain, Telisha Millender" sort="Swain, Telisha Millender" uniqKey="Swain T" first="Telisha Millender" last="Swain">Telisha Millender Swain</name></author><author><name sortKey="Davidson, Jennifer" sort="Davidson, Jennifer" uniqKey="Davidson J" first="Jennifer" last="Davidson">Jennifer Davidson</name></author><author><name sortKey="Zayzafoon, Majd" sort="Zayzafoon, Majd" uniqKey="Zayzafoon M" first="Majd" last="Zayzafoon">Majd Zayzafoon</name></author><author><name sortKey="Harris, Kevin W" sort="Harris, Kevin W" uniqKey="Harris K" first="Kevin W." last="Harris">Kevin W. Harris</name></author><author><name sortKey="Selander, Katri S" sort="Selander, Katri S" uniqKey="Selander K" first="Katri S." last="Selander">Katri S. Selander</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:97BE15C3CAAE90F9CCC7175ACC7239A5004403B4</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/pros.20562</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-B53JQ5HQ-S/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000792</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000792</idno><idno type="wicri:Area/Istex/Curation">000792</idno><idno type="wicri:Area/Istex/Checkpoint">000973</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000973</idno><idno type="wicri:doubleKey">0270-4137:2007:Ilvesaro J:toll:like:receptor</idno><idno type="wicri:Area/Main/Merge">001B01</idno><idno type="wicri:Area/Main/Curation">001A90</idno><idno type="wicri:Area/Main/Exploration">001A90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Toll like receptor‐9 agonists stimulate prostate cancer invasion in vitro</title><author><name sortKey="Ilvesaro, Joanna M" sort="Ilvesaro, Joanna M" uniqKey="Ilvesaro J" first="Joanna M." last="Ilvesaro">Joanna M. Ilvesaro</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Department of Medicine, Division of Hematology‐Oncology, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Merrell, Melinda A" sort="Merrell, Melinda A" uniqKey="Merrell M" first="Melinda A." last="Merrell">Melinda A. Merrell</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Department of Medicine, Division of Hematology‐Oncology, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Swain, Telisha Millender" sort="Swain, Telisha Millender" uniqKey="Swain T" first="Telisha Millender" last="Swain">Telisha Millender Swain</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Department of Medicine, Division of Hematology‐Oncology, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Davidson, Jennifer" sort="Davidson, Jennifer" uniqKey="Davidson J" first="Jennifer" last="Davidson">Jennifer Davidson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Department of Medicine, Division of Hematology‐Oncology, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Zayzafoon, Majd" sort="Zayzafoon, Majd" uniqKey="Zayzafoon M" first="Majd" last="Zayzafoon">Majd Zayzafoon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Department of Pathology, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Harris, Kevin W" sort="Harris, Kevin W" uniqKey="Harris K" first="Kevin W." last="Harris">Kevin W. Harris</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Department of Medicine, Division of Hematology‐Oncology, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Birmingham Veterans Affairs Medical Center, Birmingham</wicri:cityArea></affiliation></author><author><name sortKey="Selander, Katri S" sort="Selander, Katri S" uniqKey="Selander K" first="Katri S." last="Selander">Katri S. Selander</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Department of Medicine, Division of Hematology‐Oncology, University of Alabama at Birmingham, Birmingham</wicri:cityArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Alabama</region></placeName><wicri:cityArea>Correspondence address: UAB, Department of Medicine, Division of Hematology‐Oncology, WTI T558, 1824 6th Avenue South, Birmingham</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">The Prostate</title><title level="j" type="alt">PROSTATE, THE</title><idno type="ISSN">0270-4137</idno><idno type="eISSN">1097-0045</idno><imprint><biblScope unit="vol">67</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="774">774</biblScope><biblScope unit="page" to="781">781</biblScope><biblScope unit="page-count">8</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-05-15">2007-05-15</date></imprint><idno type="ISSN">0270-4137</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0270-4137</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adenocarcinoma</term><term>Brain cancer cells</term><term>Breast cancer cells</term><term>Cancer cells</term><term>Cancer immunotherapy</term><term>Chloroquine</term><term>Clinical samples</term><term>Color figure</term><term>Culture medium</term><term>Endogenous ligands</term><term>Endoplasmic reticulum</term><term>Epithelial</term><term>Epithelial cancer cells</term><term>Epithelial cells</term><term>Estradiol</term><term>Human prostate cancer</term><term>Human prostate cancer cell lines</term><term>Human prostate cancer cells</term><term>Immunohistochemical detection</term><term>Immunol</term><term>Invasion intlr9</term><term>Life technologies</term><term>Ligand</term><term>Lncap</term><term>Lncap cells</term><term>Lower wells</term><term>Microbial</term><term>Microbial components</term><term>Negative staining control</term><term>Neutralizing antibody</term><term>Normal culture medium</term><term>Novel mechanism</term><term>Nucleic acids</term><term>Pca2b cells</term><term>Pca2b prostate cancer cells</term><term>Primary antibody</term><term>Prostate</term><term>Prostate cancer</term><term>Prostate cancer cells</term><term>Prostate cancer invasion</term><term>Prostate cancer progression</term><term>Prostate cancer risk</term><term>Prostate carcinogenesis</term><term>Prostate gland</term><term>Receptor</term><term>Receptors tlr4</term><term>Steroid biochem</term><term>Stromal cells</term><term>Subcellular localization</term><term>Synthetic inhibitors</term><term>Testosterone</term><term>Testosterone tlr9 expression</term><term>Tlr9</term><term>Tlr9 agonistic</term><term>Tlr9 agonists</term><term>Tlr9 expression</term><term>Tlr9 ligands</term><term>Tlr9 subfamily</term><term>Tlrs</term><term>Various tlrs</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND: Toll‐like receptor 9 (TLR9) recognizes microbial DNA. In addition to immune cells, TLR9 expression has been detected in various cancer cells. We showed recently that TLR9 agonistic CpG‐oligonucleotides (CpG‐ODNs) induce matrix metalloproteinase‐13 (MMP‐13)‐mediated invasion in TLR9‐expressing (TLR9+) breast cancer cells. We investigated here TLR9 expression and function in human prostate cancer (CaP) cells. METHODS: TLR9 expression was detected with Western blotting and immunohistochemistry. Invasion was studied with Matrigel‐assays. MMP‐13 was assayed with ELISA. RESULTS: Human CaP cell lines and clinical samples exhibit various levels of TLR9 expression. Treatment of TLR9+, but not TLR9− CaP cells with CpG‐ODNs or bacterial DNA increased their invasion, which was inhibited with chloroquine. CpG‐ODN‐treatment also increased MMP‐13 activity and neutralizing anti‐MMP‐13 antibody prevented CpG‐ODN‐induced invasion in TLR9+ CaP cells. Estradiol up‐regulated TLR9 expression in LnCaP cells. CONCLUSIONS: TLR9‐mediated invasion may represent a novel mechanism through which infections promote prostate cancer. Prostate 67: 774–781, 2007. © 2007 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Alabama</li></region></list><tree><country name="États-Unis"><region name="Alabama"><name sortKey="Ilvesaro, Joanna M" sort="Ilvesaro, Joanna M" uniqKey="Ilvesaro J" first="Joanna M." last="Ilvesaro">Joanna M. Ilvesaro</name></region><name sortKey="Davidson, Jennifer" sort="Davidson, Jennifer" uniqKey="Davidson J" first="Jennifer" last="Davidson">Jennifer Davidson</name><name sortKey="Harris, Kevin W" sort="Harris, Kevin W" uniqKey="Harris K" first="Kevin W." last="Harris">Kevin W. Harris</name><name sortKey="Harris, Kevin W" sort="Harris, Kevin W" uniqKey="Harris K" first="Kevin W." last="Harris">Kevin W. Harris</name><name sortKey="Merrell, Melinda A" sort="Merrell, Melinda A" uniqKey="Merrell M" first="Melinda A." last="Merrell">Melinda A. Merrell</name><name sortKey="Selander, Katri S" sort="Selander, Katri S" uniqKey="Selander K" first="Katri S." last="Selander">Katri S. Selander</name><name sortKey="Selander, Katri S" sort="Selander, Katri S" uniqKey="Selander K" first="Katri S." last="Selander">Katri S. Selander</name><name sortKey="Selander, Katri S" sort="Selander, Katri S" uniqKey="Selander K" first="Katri S." last="Selander">Katri S. Selander</name><name sortKey="Swain, Telisha Millender" sort="Swain, Telisha Millender" uniqKey="Swain T" first="Telisha Millender" last="Swain">Telisha Millender Swain</name><name sortKey="Zayzafoon, Majd" sort="Zayzafoon, Majd" uniqKey="Zayzafoon M" first="Majd" last="Zayzafoon">Majd Zayzafoon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:97BE15C3CAAE90F9CCC7175ACC7239A5004403B4
|texte= Toll like receptor‐9 agonists stimulate prostate cancer invasion in vitro
}}
| This area was generated with Dilib version V0.6.33. |  |